Dren Bio

Edit info

Founded: 2019

Location: Foster City, CA

Employee range: 11 - 50

Clinical stage: Clin1

Therapy area: Blood cancers

Drug types: ONC, IMM

Lead product: DR-01

Funding: $65M B Jun 2022; $60M A Oct 2020

Investors: Aisling Capital, HBM Healthcare Investments, Pfizer, ArrowMark Partners, Revelation Partners, SR One, 8VC, Taiho Ventures, BVF Partners, Mission BioCapital, Alexandria Venture Investments

drenbio.com

linkedin.com

job board

Drug notes:

Also Clin0 autoimmune disease; DR-0201 Clin0 B-cell malignancies; DR-02 3 efforts RD/Clin0 solid tumors, RD light chain amyloidosis

About:

Dren Bio is using protein engineering technologies to develop therapeutic antibodies for cancer and autoimmune diseases. Current research suggests that many diseases can be treated if the relevant elements of the immune system can be activated. Dren’s approach is to selectively engage and deplete pathologic cells, protein aggregates or other disease-causing agents, by designing engineered antibodies. Their pipeline currently has two distinct programs. Dren’s lead program, DR-01, falls under their antibody-dependent cellular cytotoxicity program for antibody mediated killing of target cells. Their second program, Targeted Myeloid Engager and Phagocytosis Platform, uses Dren’s proprietary bispecific antibodies to engage both immune and cancer cells to support durable anti-tumor immune responses.

Jobs:

Main

Contact: recruit@workinbiotech.com